Mammalian hexokinase type I is a 100 kDa enzyme that has been considered to be evolved from an ancestral 50 kDa yeast-type hexokinase, insensitive to product inhibition, by gene duplication and fusion. According to this model, and based on many experimental data, the catalytic site is associated with the C-terminal half of the enzyme, although an allosteric site for the binding of glucose 6-phosphate could be present on the N-terminal half of the molecule. We have isolated a cDNA clone of hexokinase from a Agtl 1 human placenta library comprising 2658 bp, containing a single open reading frame of 1893 nucleotides, which encodes a truncate form of hexokinase starting from asparagine-287 to the terminal serine-917. This clone was further digested with restriction enzyme NcoI to obtain almost only the C-terminal half of human hexokinase starting from methionine-455 to the terminal amino acid and was overexpressed in active form in Escherichia coli and purified by ion-exchange h.p.l.c. The overexpressed 'mini'-hexokinase was found not only to catalyse glucose phosphorylation, but also to be inhibited by glucose 6-phosphate and other mono-and bis-phosphate sugars exactly like the complete mammalian enzyme. These results suggest that the C-terminal half of human hexokinase, in addition to the catalytic site, also contains the regulatory site and that the evolutionary relationship between the hexokinases should be reconsidered by including the appearance of a regulatory site before the gene duplication.
INTRODUCTION
Mammalian hexokinase type I (ATP: D-hexose-6-phosphotransferase, EC 2.7.1.1) is the predominant glucose-phosphorylating activity in a number of cells and tissues, including erythrocytes, platelets, brain, kidney, heart, etc. [1] [2] [3] [4] .
One of the most interesting properties of this isoenzyme is its sensitivity to product (glucose 6-phosphate) inhibition [4] [5] [6] [7] [8] . Glucose 6-phosphate sensitivity is not only important as a mechanism to influence the hexokinase activity, but also as a modulator of hexokinase intracellular distribution [4] .
Hexokinase type I has a molecular mass of about 100 kDa. This property, and the fact that yeast hexokinase has a 50 kDa molecular mass and is not significantly inhibited by glucose 6-phosphate [2] , has led several authors to suggest a mechanism of gene duplication and fusion for the appearance of hexokinase at the present time [9] [10] [11] [12] . According to this scheme the Cterminal half of the enzyme contains the catalytic site of hexokinase [13, 14] , and an allosteric site for the binding of glucose 6-phosphate could be present on the N-terminal half [15] , evolving from the originally duplicated catalytic site. Several pieces of evidence support the above conclusions. The deduced amino acid sequences of the N-and C-terminal halves of human kidney hexokinase [16] , rat brain hexokinase [17] and mouse tumour-cell hexokinase [18] show a very high sequence identity.
The regulatory site has been mapped on the N-terminus of the rat enzyme [15] , and the catalytic site was mapped on the C-terminus [13, 14] . Both the N-and C-terminal halves of all hexokinases cloned show a high sequence identity with the yeast enzyme [16] [17] [18] [19] and glucokinase [20] , a 50 kDa hexokinase isoenzyme (type IV). However, in addition to these results, a few discrepancies have also been already reported. Schwab & Wilson [21] have proposed that an ATP-binding site is determined by the sequence GSGKGA. Since this sequence, as well as residues implicated in the binding of glucose, are present in both the Nand C-terminal domains, it seems difficult to explain why a catalytic site is present only in the C-terminal and not also in the N-terminal. More recently, Arora et al. [18] have suggested a different ATP-binding domain for mice hexokinase based on the finding of a strong sequence similarity to the ATP-binding domain of cyclic AMP-dependent protein kinases. This suggestion involves the presence of a direct contact lysine residue for ATP (K-558) only in the C-terminal half of the molecule. This critical lysine has been replaced with a glutamic acid residue (E-l 10) in the N-terminal half of hexokinase, implying that this domain is capable of playing only a regulatory role and not a catalytic one. A 50-amino-acid synthetic peptide comprising this ATP-binding site was found to be able to interact with an ATP analogue [19] , confirming this supported localization for the ATP binding. To further complicate the situation, an isolated Cterminus of rat brain hexokinase was reported to contain a hexose 6-phosphate-binding site [22] . In other words, it is not at all clear whether the regulatory site is present in the C-terminus or in the N-terminus. In the present paper we report the functional expression of the C-terminal human hexokinase I cDNA in Escherichia coli and we show that the recombinant 'mini'-hexokinase, comprising only one glucose-binding site and only one putative ATP-binding site, is catalytically active and sensitive to inhibition by hexose 6-phosphates. On these bases the evolutionary relationships among hexokinases are discussed.
EXPERIMENTAL Antibodies
Human placenta hexokinase type I was purified to homogeneity as reported in [23] . The [30] . The immunoreactivity of the antiserum with the fusion proteins of positive clones was determined by Western blotting as described in [30] . DNA Protein A was iodinated to a specific radioactivity of 107 c.p.m./ ,ug as described in [35] .
The TG1 E. coli strain containing the mini-hexokinase expression plasmid pJHK502 was grown at 28°C and shaken at 200 rev./min to an A600 of about 0.4. The temperature was then shifted to 42 'C and the cells collected by centrifugation at 3000 g for 15 min. The resultant pellet was resuspended (1 vol . ofcells/5 vol. of buffer) in a solution containing 15 mM-Tris/HCl, pH 8.0, 1 mM-EDTA, 50 mM-glucose, 0.50% (v/v) Triton X-100, 3 mM-mercaptoethanol, 9 % (v/v) glycerol, lysozyme (2 mg/ml), 1 mM-phenylmethanesulphonyl fluoride, leupeptin (15 jug/ml) and 0.1 mM-pepstatin. The cell suspension was shaken at 0°C for 30 min and then sonicated four times for 15 s at 40 W. Sonicated extracts were then centrifuged for 1 h at 20000 g and 4 'C. The supernatants were then used for hexokinase assay (see below), protein assay [36] and ion-exchange h.p.l.c. (see below). As controls for expression experiments, E. coli cells transformed with a plasmid lacking the mini-hexokinase gene and the uninduced cells were used. The bacterial and recombinant hexokinases were purified by an ion-exchange chromatography on a Toyopearl DEAE-650M (2.2 cm x 25 cm) column to separate the two enzymes, followed by a single-step affinity chromatography on a 1 cm x 4 cm column of Sepharose-N-aminohexanoylglucosamine for the bacterial enzyme or a combination of affinity chromatography and dye-ligand chromatography on a 1 cm x 4 cm Blue A (Matrex Gel Blue A; Amicon) column as already described for the purification of human placenta hexokinase [23] .
Hexokinase assay
In the fractions of bacterial extract, the hexokinase activity was measured at 37 'C spectrophotometrically in a system coupled with glucose 6-phosphate dehydrogenase (EC 1.1.1.49) or, in the glucose 6-phosphate inhibition studies, in a coupled enzyme system with pyruvate kinase (EC 2.7.1.40) and lactate dehydrogenase (EC 1.1.1.28) as described in [5] . One [5] . Vol. 285
Ion-exchange chromatography The mini-hexokinase expressed by bacteria was partially purified by h.p.l.c. ion-exchange chromatography on a 7.5 mm x 75 mm Bio-Gel TSK-DEAE-5PW column (Bio-Rad). The column was equilibrated in 5 mM-sodium potassium phosphate buffer, pH 7.55, containing 10 mM-glucose, 3 mMmercaptoethanol, 0.5 mM-EDTA, 9 % (v/v) glycerol and operated at 1 ml/min. Hexokinase activity was eluted by a KC1 linear gradient (0-0.4 M) in the equilibrating buffer in 400 min. Fractions (1 ml each) were collected and assayed for hexokinase activity.
RESULTS cDNA cloning of human hexokinase
A Agtl 1 cDNA library from human placenta poly(A)+ RNA was screened for expression of fusion proteins reacting with rabbit polyclonal antibodies raised against type I human hexokinase. Screening of the library was performed as described in [30] . From 1.2 x 106 recombinants, five independent immunoreactive clones were isolated. Western-blot analysis confirmed the presence of immunoreactive materials in the corresponding lacZ fusion proteins. One of these clones was used as a probe to screen the same library by hybridization and a cDNA clone of approx. 2.7 kb was isolated (HK-16).
The nucleotide sequence of HK-16 is reported in Fig. 1 Overexpression and characterization of a human mini-hexokinase The aim of the present study was the localization of the glucose 6-phosphate regulatory site on human hexokinase. To verify whether or not during hexokinase evolution the regulatory site appeared in the N-terminal domain, as suggested by many authors, we expressed only the C-terminal half of human hexokinase, expecting a non-regulated enzyme. These experiments were performed in 80 mM-Tris/HCl, pH 7.2, at 37 'C. The glucose concentration was 2.5 mM and that of free Mg2+ was 5 mM. Glucose 1,6-bisphosphate or glucose 6-phosphate were at the following concentrations: 0, 0 /LM; 0, 50,UM; A. 100 /M. HK-16 was digested with NcoI, giving a nucleotide sequence that encodes only the C-terminal domain of human hexokinase starting from methionine-455. This fragment was ligated into the expression plasmid pJLA502 under the A-bacteriophage promoters PR and PL At 28°C, transcriptional initiation is repressed by the cIts857 gene product and can be achieved by shifting the temperature to 42 'C. After 90 min at 42 'C a large amount of protein was produced in the E. coli cells transformed with this plasmid. This protein band on SDS/PAGE has an apparent Mr of 52 kDa, as expected for this truncate form of hexokinase (Fig.  2a) . Western-blot analysis confirmed that the overexpressed protein was indeed a truncate form of human hexokinase, since it reacts with a monospecific rabbit anti-(human hexokinase) antibody (Fig. 2b) . E. coli cells transformed with this expression vector contained a biologically active hexokinase with a specific activity of 125 munits/mg of protein, whereas control cells had a hexokinase activity of only 46 munits/mg of protein. This specific activity (125 munits/mg of protein) can be obtained only if, during the induction experiment, the cells are maintained at an A600 lower than 1.2. In experiments where the induction by temperature shift was performed at higher cell densities, or for a period of time longer than 1.5 h, the recombinant protein in the Vol. 285 gel was approximately the same, but the specific activity was considerably lower (70-100 munits/mg of protein). This result suggests that exposure to high temperature or inductions performed at high bacterial densities favour the intracellular inactivation of the recombinant hexokinase. That indeed most of the recombinant hexokinase was present in E. coli in an inactive form has been confirmed by laser-scanning-densitometric analysis of SDS/polyacrylamide gels stained with Coomassie Blue. By this method the expression of the mini-hexokinase was found to be 7.5 % of total proteins, a value much higher than expected on the basis of the hexokinase specific activity measured in the bacterial lysate. The inactivation of overexpressed recombinant proteins in E. coli is a well-known phenomenon that is due to inappropriate folding and/or formation of highly aggregated insoluble material. In some cases these products are 'rescuable' by denaturation-renaturation, but several attempts performed on our samples have not significantly improved the amounts of active recombinant hexokinase obtained. The overexpressed active mini-hexokinase was then purified by ion-exchange h.p.l.c. Two peaks of activity were obtained (Fig. 3) The glucose 1,6-bisphosphate inhibition can also be partially relieved (by 12 %) by orthophosphate (results not shown).
Since it is possible that the partially purified human minihexokinase is a complex with the bacterial enzyme, we have determined the molecular mass of the expressed protein under native conditions. Gel filtration on Ultragel AcA44 (0.8 cm x 44 cm) of the first peak, performed as described in [23] , provided values of 50 + 5 kDa, a value that is in agreement with a monomeric nature of the mini-hexokinase. Furthermore, inhibition studies by phosphorylated sugars performed after the gel-filtration experiment confirmed the values reported in Table 1 .
Purification of the recombinant and bacterial hexokinases Expression in E. coli of the mini-hexokinase results in the production of significant amounts of recombinant protein (see above); however, only a small percentage of this seems to be catalytically active. In an attempt to purify to homogeneity the catalytically active recombinant enzyme we used a DEAE ionexchange column (Toyopearl 650M) equilibrated with a buffer system identical with that reported above for h.p.l.c. As eluting conditions we used a linear 0-0.4M-KCI gradient in a total volume of 700 ml. The bacterial and recombinant enzymes were identified by the criteria described above [immunoinactivation by a specific anti-(human hexokinase) antibody and inhibition by phosphorylated sugars] and further purified by a single-step affinity chromatography on Sepharose-N-aminohexanoylglucosamine (for the bacterial enzyme) or a combination of affinity chromatography and dye-ligand chromatography on a Blue A column for the recombinant enzyme. Details of these procedures were as previously described [23] . Elution from the affinity-chromatography column was by glucose (50 mM), whereas elution from the Blue A column was with 1.5 mM glucose 6-phosphate. The specific activity of the bacterial enzyme was 700 units/mg of protein and a single protein band was present in the SDS/polyacrylamide gel, whereas the recombinant hexokinase showed a specific activity of 294 units/mg of protein (ranging from 214 to 381 units/mg of protein in five different preparations) and a major protein band in the gel. The bacterial enzyme was insensitive to inhibition by phosphorylated sugars, whereas the recombinant protein was inhibited with values similar to those reported in Table 1 .
DISCUSSION
One of the most interesting features of mammalian hexokinase type I is its sensitivity to inhibition by glucose 6-phosphate at physiological concentrations [4] [5] [6] [7] [8] . This property is not possessed by the yeast enzyme. Furthermore, the mammalian enzyme has a molecular mass of about 100 kDa, a value almost twice that of the yeast hexokinase, leading several authors to suggest a mechanism of gene duplication and fusion for the evolution of hexokinases [9] [10] [11] [12] . Recent results on the derived amino acid sequences of hexokinases type I cloned from rat brain [17] , mouse hepatoma cells [18] and human kidney [16] have confirmed the very high sequence identity among the N-and C-terminal halves of the mammalian enzyme and among each half of the molecule and the yeast enzyme. These studies however, although suggesting a possible localization of the glucose 6-phosphate regulatory site on the N-terminal half of the enzyme, have not confirmed it. Studies on rat brain hexokinase have indeed shown that the regulatory site binding glucose 6-phosphate is associated with the N-terminal half of the enzyme [15] ; however isolation of the C-terminal half has revealed an unexpected sensitivity to glucose 6-phosphate inhibition [22] that is difficult to reconcile with the considerations mentioned above. Here we report a direct proof for the existence of a glucose 6-phosphate regulatory site on the C-terminal half of the enzyme obtained by cloning and expression of the C-terminal human hexokinase domain.
The main problem that should now be solved concerns the previously reported evidence of a single high-affinity glucose 6-phosphate-binding site for each 100 kDa enzyme molecule [7, 8, 37] . Some authors [22, 38, 39] have suggested that, although each mammalian hexokinase type I molecule contains two glucose 6-phosphate regulatory sites, only one of these (namely that localized in the N-terminal half) would be functioning in the intact enzyme, whereas the other would be latent. Although this hypothesis is fascinating, we cannot exclude the possibility that only the regulatory site in the catalytic domain could be implicated in hexokinase regulation. In our opinion the almost identical K, values of the native and of the recombinant minihexokinase for several phosphorylated sugars, as reported here, confirm the existence of a functional glucose 6-phosphate-binding site in the C-terminal half of hexokinase. Glucose 6-phosphate binding at the N-terminal half could possibly be involved in the regulation of the intracellular distribution of hexokinase [4] . The second implication of the results we have reported here concerns the evolutionary relationship between the hexokinases. The first consideration is that the classical view of a mammalian enzyme arising by gene duplication and fusion with the transformation of one catalytic site into the regulatory site at the Nterminal half is not tenable. An alternative view, and one that seems to be more reasonable, is that the mammalian hexokinase arises from a 50 kDa enzyme that has already acquired a sensitivity to inhibition by glucose 6-phosphate [22] . That indeed this kind of hexokinase exists was first reported by Machizuki & Hori [40, 41] in 1977, who described a 50 kDa hexokinase with a glucose 6-phosphate-inhibitory site in the marine organism Asterias (starfish). Our results provide further support to this view, but several questions remain unsolved, and further studies are needed, along the line presented in here, to confirm directly the existence of further important binding sites on the enzyme.
